The global cell-based assays market is expected to reach USD 18,329.37 million by 2020 from USD 10,799.53 million in 2015, growing at a CAGR of 11.16% between 2015 and 2020. The product segments included in this report are consumables, instruments, services and software. The consumables segment is further divided on the basis of type into reagents and assay kits, cell lines, micro plates. Reagents and assay kits segment is further divided into reporter gene assays, second messenger assays, cell growth assays, cell death assays and other assays. Cell lines segment is further classified into immortalized cell lines, primary cell lines and stem cell lines. On the basis of applications; the report is segmented into basic research, drug discovery, predictive toxicology, ADME studies and other applications. The drug discovery had the largest share of the cell-based assays market in 2015. The predictive toxicology is expected to be one of the fastest growing applications between 2015 and 2020.
The key driver for this market is increased R&D spending on research. Furthermore, growing benefits of cell-based assays over other methods, their increasing adoption in drug discovery, and advancements in automation and high-throughput techniques will aid market growth.
The report provides qualitative insights about key market shares, growth rates, and market drivers for all important sub segments. It maps the market sizes and growth rates of each sub segment and identifies the segments poised for rapid growth in each of the geographic segments. The report also includes company profiles of the market leaders. These company profiles include financial performances, product portfolios, and market developments for each company. The report also provides a competitive landscape of the cell-based assays market. The competitive landscape covers the growth strategies adopted by the industry players over the last four years. It also includes analysis of industry developments like new product launches, expansions, agreements and collaborations and acquisitions.
